



7-8-2013

To,
The Manager, Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza"
Bandra-Kurla Complex,
Bandra – East,
Mumbai

Sub: Unaudited Financial Results for the Quarter ended 30th June, 2013

Dear Sir,

With reference to the captioned matter, we enclose herewith the Unaudited Financial Results of the Company for the Quarter ended 30th June, 2013, duly reviewed by the statutory auditors of the Company and approved by Board of Directors of the Company at its meeting held today.

We also enclose herewith the press release dated 7th August, 2013.

Please take note of the same.

Thanking you,
For Alembic Pharmaceuticals Limited


R. K. Baheti
Director-Finance
& Company Secretary

Encl.: A/a

ALEMBIC PHARMACEUTICALS LIMITED


REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : (0265) 2280550, 2280880, • FAX : (0265) 2282505
www.alembic-india.com • E-mail : alembic@alembic.co.in



ALEMBIC PHARMACEUTICALS LIMITED
 Regd. Office: Alembic Road, Vadodara 390 003
UNAUDITED FINANCIAL RESULTS
FOR THE PERIOD ENDED 30th JUNE, 2013

Rs. in lacs

	Particulars	STANDALONE			
		Quarter Ended			Year Ended
		June-13	March-13	June-12	March-12
		(UnAudited)	(UnAudited)	(UnAudited)	(Audited)
PART- I					
1	(a) Net Sales / Income from Operations				
	Domestic	24,400	23,624	22,870	100,877
	Exports	18,445	14,177	11,200	48,952
	Total	42,845	37,801	34,070	149,829
	Less : Excise Duty	218	178	199	875
	Net Sales / Income from Operations	42,627	37,623	33,871	148,954
	(b) Other Operating Income	57	150	56	309
	Total Income from Operations	42,684	37,773	33,927	149,262
2	Expenses				
	(a) Decrease/(Increase) in stock in trade and work in progress	(1,303)	2,550	(142)	2,134
	(b) Consumption of Raw Materials & Packing Materials	13,597	10,810	11,168	47,030
	(c) Purchase of traded goods	4,848	3,348	4,068	18,559
	(d) Employees' Cost	5,636	5,077	4,495	19,379
	(e) Research and Development Expense	2,070	2,200	1,389	7,363
	(f) Excise Duty	78	171	114	100
	(g) Other Expenditure	10,227	7,446	8,006	32,222
	Total Expenses	38,288	31,602	29,098	124,886
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	7,429	6,171	4,829	24,376
4	Other Income	2	7	21	393
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	7,431	6,178	4,850	24,769
6	Depreciation	953	864	866	3,496
7	Interest (Net)	147	183	574	1,457
8	Net Profit / (Loss) from Ordinary Activities before Tax	6,331	5,131	3,410	19,816
9	Tax Expense				
	Less : Provision for Current Tax	1,327	1,024	687	3,975
	Less /Add : Provision for Deferred Tax Liability/(Assets)	57	136	(5)	96
10	Net Profit / (Loss) from Ordinary Activities after Tax	4,947	3,971	2,728	15,745
11	Paid up Equity Share Capital	3,770	3,770	3,770	3,770
	(Face value of share Rs. 2/-)				
12	Reserves excluding Revaluation Reserve	-	-	-	42,206
13	Basic & Diluted EPS (Not Annualised)	2.62	2.11	1.45	8.35
14	Debt Equity Ratio				0.36
PART- II					
A	Particulars of Shareholding				
1	Public Shareholding				
	- Number of Shares	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding				
	- Fully Non - Encumbered				
	- Number of Shares	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter ended on 30th June, 2013			
	Pending at the beginning of the quarter			NIL	
	Received during the quarter			1	
	Disposed of during the quarter			1	
	Remaining unresolved at the end of the quarter			NIL	





ALEMBIC PHARMACEUTICALS LIMITED
 Regd. Office: Alembic Road, Vadodra 390 003
UNAUDITED FINANCIAL RESULTS
FOR THE PERIOD ENDED 30th JUNE, 2013

		Rs. in Lacs			
		CONSOLIDATED			
Particulars		Quarter Ended			Year Ended
		June-13	March-13	June-12	March-12
PART- I		(UnAudited)	(UnAudited)	(UnAudited)	(Audited)
1	(a) Net Sales / Income from Operations				
	Domestic	24,400	23,824	22,870	100,877
	Exports	18,477	14,212	13,936	81,723
	Total	42,877	37,836	36,806	152,600
	Less : Excise Duty	218	178	199	875
	Net Sales / Income from Operations	42,659	37,658	36,607	151,725
	(b) Other Operating Income	87	150	58	309
Total Income from Operations		42,746	37,808	36,665	152,034
2	Expenses				
	(a) Decrease/(Increase) in stock in trade and work in progress	(1,303)	2,550	(142)	2,134
	(b) Consumption of Raw Materials & Packing Materials	13,597	10,810	11,168	47,030
	(c) Purchase of traded goods	4,849	3,348	6,415	18,906
	(d) Employees' Cost	8,436	8,077	4,498	18,379
	(e) Research and Development Expense	2,241	2,200	1,389	7,363
	(f) Excise Duty	79	171	114	100
	(g) Other Expenditure	10,289	7,094	7,886	31,826
Total Expenses		38,568	31,250	31,435	126,838
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	7,148	6,558	5,228	25,195
4	Other Income	2	7	21	393
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	7,150	6,565	5,249	25,588
6	Depreciation	953	854	866	3,497
7	Interest (Net)	147	183	574	1,457
8	Net Profit / (Loss) from Ordinary Activities before Tax	6,050	5,518	3,809	20,635
9	Tax Expense				
	Less : Provision for Current Tax	1,328	1,017	731	4,014
	Less/(Add) : Provision for Deferred Tax Liability/(Assets)	87	136	(5)	96
10	Net Profit / (Loss) from Ordinary Activities after Tax	4,684	4,365	3,083	16,525
11	Paid up Equity Share Capital (Face value of share ₹ 2/-)	3,770	3,770	3,770	3,770
12	Reserves excluding Revaluation Reserve	-	-	-	48,824
13	Basic & Diluted EPS (Not Annualised)	2.47	2.32	1.64	8.77
14	Debt Equity Ratio				0.33
PART- II					
A	Particulars of Shareholding				
1	Public Shareholding				
	- Number of Shares	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding				
	- Fully Non - Encumbered				
	- Number of Shares	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13
B INVESTOR COMPLAINTS		Quarter ended on 30th June, 2013			
	Pending at the beginning of the quarter			NIL	
	Received during the quarter			1	
	Disposed of during the quarter			1	
	Remaining unresolved at the end of the quarter			NIL	



Notes :

- 1 The above results, have been duly reviewed by Statutory Auditors, were recommended by the Audit Committee and were approved by the Board of Directors. However, the unaudited results of the Subsidiary included in above have not been reviewed by Statutory Auditors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website www.alembic-india.com.
- 2 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 3 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara
Date : 7th August, 2013

For Alembic Pharmaceuticals Limited



Chirayu Amin
Chairman and Managing Director

Visit us at www.alembic-india.com



K. S. AIYAR & CO

CHARTERED ACCOUNTANTS

F-7 Laxmi Mills
Shakti Mills Lane (Off Dr E Moses Rd)
Mahalaxmi Mumbai 400 011 India
Tel : 91 22 2493 2502 / 6655 1770
Fax : 91 22 6655 1774
Grams : VERIFY
www.KSAiyar.com
Mail@KSAiyar.com

To,
The Board of Directors;
Alembic Pharmaceuticals Limited;
Alembic Road,
Vadodara 390 003.

RE: **LIMITED REVIEW OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE
QUARTER ENDED 30th June, 2013 PREPARED BY THE COMPANY.**

1. **INTRODUCTION**

We have reviewed the accompanying statement of unaudited consolidated financial results of **Alembic Pharmaceuticals Limited** for the quarter ended on **30th June, 2013** except for the disclosures regarding public shareholding and Promoter and Promoter Group shareholding which have been traced from disclosures made by the management, but have neither been reviewed nor been audited by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to issue a report on this Statement based on our review.

2. **SCOPE OF REVIEW**

2.1 We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether this Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

2.2 We report that the consolidated unaudited financial results have been prepared by the Company's management in accordance with the requirements of Accounting Standard (AS) 21 – Consolidated Financial Statements issued by the Central Government under Companies (Accounting Standards) Rules, 2006 and on the basis of the separate unaudited financial results of its 100% Subsidiary i.e. Alembic Global Holding SA, Switzerland which have not been reviewed.

Offices also at
Chennai Kolkata Goa
Bangalore Coimbatore

K. S. AIYAR & CO


CHARTERED ACCOUNTANTS

F-7 Laxmi Mills
Shakti Mills Lane (Off Dr E Moses Rd)
Mahalaxmi Mumbai 400 011 India
Tel : 91 22 2493 2502 / 6655 1770
Fax : 91 22 6655 1774
Grams : VERIFY
www.KSAiyar.com
Mail@KSAiyar.com

3. CONCLUSION

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.S.Aiyar & Co.
Chartered Accountants
FRN: 100186W



Rajesh S Joshi
Partner
M.No. 38526

Place: Vadodara
Date: 7th August, 2013

Offices also at
Chennai Kolkata Goa
Bangalore Coimbatore

For Immediate Release

**Alembic Pharmaceuticals Limited
Consolidated Results for quarter ended 30.06.2013**

**Revenues up by 16% at Rs 429 crores
PBT up by 59% at Rs 61 crores**

Editors Synopsis

Quarter ended 30th June, 2013

- **Net sales up 16% at Rs 429 crores for the quarter against Rs. 368 crores in corresponding quarter last year**
- **PBT at Rs 61 crores, up by 59% from Rs 38 crores in corresponding quarter last year**
- **Domestic Branded formulations sales up by 15% for the quarter at Rs. 196 crores**
- **International generics sales up by 86% for the quarter at Rs. 85 crores**
- **EBITDA margin increased to 17% for the quarter from 14% in corresponding quarter last year**
- **Net profit after tax grew by 51% for the quarter at Rs. 47 crores vis-à-vis Rs. 31 crores in corresponding quarter last year**

Vadodara, 7th Aug, 2013

Alembic Pharmaceuticals Limited reported a 16% Increase in revenues to Rs 429 crores for the quarter ended 30th June 2013, compared to Rs 368 crores in the corresponding quarter last year.

The Company posted 59% growth in Profit before Tax at Rs 61 crores for the quarter ended 30th June 2013 against Rs 38 crores posted in corresponding quarter last fiscal.

The Net Profit grew by 51% at Rs. 47 crores for the quarter ended 30th June 2013 against Rs. 31 crores in corresponding quarter last fiscal.

Domestic Branded Formulations Business

The Domestic Branded Formulations business grew by 15% to Rs. 196 crores against Rs. 170 crores in the corresponding quarter of the previous year.

As per ORG IMS, Alembic has maintained market share of 1.79%.

Chronic and Acute segments grew by 26% and 3% respectively in current year (MAT-June 13) versus Industry growth rate of 12% and 7% respectively.

International Generics

International generics grew by 86% to Rs. 85 crores against Rs. 46 crores over the corresponding quarter last year.

Desvenlafaxine Base Extended Release tablets has started receiving attention from key customers in US and sales is expected to get slowly ramp up in the next few quarters.

During the quarter 2 ANDA approvals were received. Cumulative ANDA/NDA filings at 57. Cumulative ANDA/NDA approvals now stands at 26.

API

For the quarter, Export API recorded sales of Rs. 87 crores against Rs. 83 crores while domestic API recorded sales of Rs. 21 crores against Rs. 31 crores in corresponding quarter last year. Company filed one US DMF during the quarter. Cumulative filing now stand at 61.

Summary of total revenue (consolidated) for the quarter is as under:

(Rs. in crores)

Particulars	Q1 FY14	Q1 FY13	% Change
Formulation			
Domestic Branded	195.79	170.26	15%
Domestic Generic & NSA	25.43	26.98	(-)6%
International Generics	85.47	46.05	86%
International Branded	12.21	7.55	62%
API			
Domestic	20.21	30.47	(-)34%
International	86.76	83.48	4%
Export incentives & Others	2.90	3.27	
Total	428.77	368.06	16%

The Profit break-up for the quarter is as under:

(Rs. in crores)

Particulars	Q1 FY14	Q1 FY13	% Change
Operating Income	71.48	52.28	37%
Profit Before Tax	60.50	38.09	59%
Net Profit after Tax	46.64	30.83	51%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically Integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered In India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world Including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 3650 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information:

Mitanshu Shah

Phone: +91 265 – 3007630

Email: mitanshu.shah@alembic.co.in

Alembic Pharmaceuticals Limited